SNS Insider Unveils Strategic Insights into the U.S. Lipid Nanoparticles Market's Rapid Growth—Valued at USD 333.94 Million in 2023—As the U.S. Leads More Than 38% of Global Share Amid Explosive ...

Cambridge, Massachusetts-based Alnylam specializes in RNA interference drugs, therapies that deliver small pieces of RNA to “silence” a gene, knocking down production of a disease-causing protein.

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics ... Opponents included Sanofi-Aventis Deutschland GmbH, Silence Therapeutics AG, and BASF SE. Inventors on the patent are David P. Bartel, ...

The Silence team supported by top cardiologists ... Finally, during 2024, we recorded the remaining royalty revenue from Alnylam of approximately $144,000. The expenses related to our partner ...

Its medicines, including ONPATTRO, GIVLAARI, OXLUMO, and AMVUTTRA, target and silence specific genes that cause conditions like hereditary ATTR amyloidosis and acute hepatic porphyria. Alnylam ...

Alnylam Pharmaceuticals ... Assuming approval, AMVUTTRA will be the first and only RNAi silence approved for both ATTR-CM and hATRR-PN, one that delivers rapid knockdown of TTR, working upstream ...

Alnylam Pharmaceuticals is a leader in RNA interference (RNAi), a cutting-edge technology that targets RNA to silence genes involved in diseases. It has a strong catalog of approved products and a ...

The world’s first RNAi therapeutic, discovered and developed by Alnylam Pharmaceuticals ... of RNAi therapeutics can direct the process to silence genes that cause or contribute to disease.

On Tuesday, Maraganore launched a start-up, City Therapeutics, that builds on his 20-year career at Alnylam by making smaller versions of the RNA molecules that silence genes to treat diseases.